檢索結果 - Scott D. Berkowitz

Refine Results
  1. 1
    Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

    Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications 由 Dagmar Kubitza, Scott D. Berkowitz, Frank Misselwitz

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Glycoprotein IIb/IIIa Integrin Blockade

    Glycoprotein IIb/IIIa Integrin Blockade 由 Mina Madan, Scott D. Berkowitz, James E. Tcheng

    出版 1998
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients

    Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients 由 Richard J. Friedman, Susanne Hess, Scott D. Berkowitz, Martin Homering

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome

    Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome 由 Ulrich Budde, JA Dent, Scott D. Berkowitz, ZM Ruggeri, TS Zimmerman

    出版 1986
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

    Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. 由 Judith Dent, Scott D. Berkowitz, Jerry Ware, C K Kasper, Zaverio M. Ruggeri

    出版 1990
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.

    Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin. 由 Scott D. Berkowitz, J Dent, James R. Roberts, Yoshihiro Fujimura, EF Plow, Koiti Titani, Zaverio M. Ruggeri, T S Zimmerman

    出版 1987
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

    Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty 由 Jeffrey I. Weitz, Rupert Bauersachs, Bastian Becker, Scott D. Berkowitz, Maria Cecília S. Freitas, Michael R. Lassen, Carola Metzig, Gary E. Raskob

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization

    Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization 由 Scott D. Berkowitz, David C. Sane, Kristina N. Sigmon, Jane H. Shavender, Robert A. Harrington, James E. Tcheng, Eric J. Topol, Robert M. Califf

    出版 1998
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction

    Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction 由 Scott D. Berkowitz, Christopher B. Granger, Karen S. Pieper, Kerry L. Lee, Joel M. Gore, Maarten L. Simoons, Paul W. Armstrong, Eric J. Topol, Robert M. Califf

    出版 1997
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    NAVIGATE ESUS: Phase-III RCT assessing prevention of stroke and systemic embolism in patients with embolic stroke of undetermined source

    NAVIGATE ESUS: Phase-III RCT assessing prevention of stroke and systemic embolism in patients with embolic stroke of undetermined source 由 Sebastián F. Ameriso, Pablo M. Lavados, Antonio Araúz, Rubens José Gagliardi, Ashkan Shoamanesh, C. Pater, Hardi Mundl, Scott D. Berkowitz, Stuart J. Connolly, Robert G. Hart

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study

    Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-bl... 由 Clifford W. Colwell, Scott D. Berkowitz, Bruce L. Davidson, Paul A. Lotke, Jeffrey S. Ginsberg, Jay R. Lieberman, Jacqueline Neubauer, Jennifer McElhattan, Gary Peters, C. W. Francis

    出版 2003
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial

    Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial 由 George Ntaios, Lesly A. Pearce, Roland Veltkamp, Mukul Sharma, Scott E. Kasner, Eleni Korompoki, Haralampos Milionis, Hardi Mundl, Scott D. Berkowitz, Stuart J. Connolly, Robert G. Hart

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients

    Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients 由 Daniel B. Mark, Patricia A. Cowper, Scott D. Berkowitz, Linda Davidson‐Ray, Elizabeth R. DeLong, Alexander G.G. Turpie, Robert M. Califf, Beth Davison Weatherley, Marc Cohen

    出版 1998
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement

    Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement 由 Charles W. Francis, Scott D. Berkowitz, Philip C. Comp, Jay R. Lieberman, Jeffrey S. Ginsberg, Guy D. Paiement, Gary Peters, Anne W. Roth, Jennifer McElhattan, Clifford W. Colwell

    出版 2003
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

    Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies 由 Martin H. Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Gary E. Raskob, Scott D. Berkowitz, Philip S. Wells

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease

    Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease 由 Eric Kaplovitch, John W. Eikelboom, Leanne Dyal, Victor Aboyans, Maria Teresa B. Abola, Peter Verhamme, Álvaro Avezum, Keith A.A. Fox, Scott D. Berkowitz, Shrikant I. Bangdiwala, Salim Yusuf, Sonia S. Anand

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions

    Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions 由 Mario Enrico Canonico, Raffaele Piccolo, Marisa Avvedimento, Attilio Leone, Salvatore Esposito, Anna Franzone, Giuseppe Giugliano, Giuseppe Gargiulo, Connie N. Hess, Scott D. Berkowitz, Judith Hsia, Plinio Cirillo, Giovanni Esposito, Marc P. Bonaca

    出版 2023
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  18. 18
    Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

    Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial 由 Tamar I. de Vries, John W. Eikelboom, Jackie Bosch, Jan Westerink, Jannick A N Dorresteijn, Marco Alings, Leanne Dyal, Scott D. Berkowitz, Yolanda van der Graaf, Keith A.A. Fox, Frank L.J. Visseren

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source

    Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source 由 Hooman Kamel, Lesly A. Pearce, George Ntaios, David J. Gladstone, Kanjana Perera, Risto O. Roine, Elena Meseguer, Ashkan Shoamanesh, Scott D. Berkowitz, Hardi Mundl, Mukul Sharma, Stuart J. Connolly, Robert G. Hart, Jeff S. Healey

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin

    On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin 由 Christopher B. Fordyce, Anne S. Hellkamp, Yuliya Lokhnygina, Samuel M. Lindner, Jonathan P. Piccini, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Keith A.A. Fox, Kenneth W. Mahaffey, Christopher C. Nessel, Daniel E. Singer, Manesh R. Patel

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: